Regeneron Pharmaceuticals, Inc. REGN

NAS: REGN | ISIN: US75886F1075   8/06/2023
750,12 USD (+1,56%)
(+1,56%)   8/06/2023

19 mei 2023 · High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023 · Persbericht

15 maart 2023 · Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease · Persbericht

24 januari 2023 · Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition · Persbericht

23 december 2022 · Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer · Persbericht

21 december 2022 · Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine · Persbericht

19 december 2022 · Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference · Persbericht

16 december 2022 · Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis · Persbericht

15 december 2022 · Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis · Persbericht

12 december 2022 · Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial · Persbericht

12 december 2022 · Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma · Persbericht

12 december 2022 · Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year · Persbericht

11 december 2022 · Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH · Persbericht

1 december 2022 · Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types · Persbericht

30 november 2022 · Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review · Persbericht

22 november 2022 · Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology · Persbericht

17 november 2022 · Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer · Persbericht

11 november 2022 · Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis · Persbericht

8 november 2022 · Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) · Persbericht

5 november 2022 · Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration · Persbericht

3 november 2022 · Regeneron Announces Investor Conference Presentations · Persbericht

Mijn selecties